| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
865,460 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
39,326 |
485,736 |
| Total Sell Value |
$0 |
$0 |
$8,245,949 |
$88,282,436 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
18 |
71 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-09-09 |
4 |
B |
$50.33 |
$12,917,842 |
I/I |
256,220 |
39,260,675 |
2.25 |
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-09-08 |
4 |
AS |
$50.08 |
$1,565,977 |
D/D |
(31,269) |
638,835 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-09-08 |
4 |
OE |
$10.29 |
$321,758 |
D/D |
31,269 |
648,307 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-09-08 |
4 |
B |
$49.18 |
$10,579,529 |
I/I |
211,093 |
39,030,368 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-09-07 |
4 |
B |
$47.27 |
$2,889,689 |
I/I |
59,560 |
38,840,624 |
2.25 |
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-09-06 |
4 |
AS |
$44.84 |
$529,007 |
D/D |
(11,653) |
617,038 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-09-06 |
4 |
OE |
$4.45 |
$200,776 |
D/D |
23,957 |
622,449 |
|
- |
|
| Gryska David W |
Director |
– • – |
2016-09-06 |
4 |
OE |
$10.20 |
$102,000 |
D/D |
10,000 |
37,650 |
|
- |
|
| Cline Darren S |
EVP, Commercial |
• – – |
2016-09-06 |
4 |
S |
$46.01 |
$248,307 |
D/D |
(5,397) |
51,576 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-09-06 |
4 |
B |
$44.98 |
$6,580,527 |
I/I |
143,363 |
4,643,343 |
2.25 |
- |
|
| Himes Vaughn B |
EVP, Proc Svcs & Tech Ops |
• – – |
2016-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
9,600 |
135,379 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2016-08-27 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
51,400 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-08-27 |
4 |
A |
$0.00 |
$0 |
D/D |
72,000 |
604,734 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2016-08-27 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
209,445 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2016-08-27 |
4 |
A |
$0.00 |
$0 |
D/D |
29,000 |
87,767 |
|
- |
|
| Himes Vaughn B |
EVP, Proc Svcs & Tech Ops |
• – – |
2016-08-27 |
4 |
A |
$0.00 |
$0 |
D/D |
17,000 |
125,779 |
|
- |
|
| Drachman Jonathan G |
CMO & EVP, R & D |
• – – |
2016-08-27 |
4 |
A |
$0.00 |
$0 |
D/D |
29,000 |
113,255 |
|
- |
|
| Cline Darren S |
EVP, Commercial |
• – – |
2016-08-27 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
56,973 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2016-08-23 |
4 |
S |
$48.00 |
$604,272 |
D/D |
(12,589) |
58,767 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2016-08-23 |
4 |
OE |
$26.10 |
$99,989 |
D/D |
3,831 |
71,356 |
|
- |
|
| Cline Darren S |
EVP, Commercial |
• – – |
2016-08-22 |
4 |
AS |
$46.59 |
$82,652 |
D/D |
(1,774) |
40,973 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2016-08-22 |
4 |
AS |
$46.59 |
$252,102 |
D/D |
(5,411) |
67,525 |
|
- |
|
| Drachman Jonathan G |
CMO & EVP, R & D |
• – – |
2016-08-22 |
4 |
AS |
$46.59 |
$185,943 |
D/D |
(3,991) |
84,255 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-08-22 |
4 |
AS |
$46.59 |
$1,089,337 |
D/D |
(23,381) |
532,734 |
|
- |
|
| Himes Vaughn B |
EVP, Proc Svcs & Tech Ops |
• – – |
2016-08-22 |
4 |
AS |
$46.59 |
$185,943 |
D/D |
(3,991) |
108,779 |
|
- |
|
1805 Records found
|
|
Page 30 of 73 |
|
|
